News
Regeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...
The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...
Stocktwits on MSN11h
CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory PanelThe Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
PORTLAND, OR, UNITED STATES, July 3, 2025 /EINPresswire.com/ -- (Global value: USD 5.4 billion (2021) → USD 7.9 billion (2031) | CAGR 3.8 %) The growth of paresthesia treatment market share is driven ...
The Business Research Company's Farber's Disease Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Save 30% on all global market reports with code ONLINE30 - stay informed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback